Close Menu
Less than a month after Targeted Genetics announced that it had acquired the full rights to the Huntington’s disease therapy it had been working on with Merck subsidiary Sirna Therapeutics, the company’s President and CEO Stewart Parker this week said the firm is working to expand the number of RNAi programs in its pipeline.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.